Gilead Sciences, Inc. Price Today
Gilead Sciences, Inc.
GILD
Healthcare
$98.14B
💰
Market Cap
17.8
💸
Price to Earnings
$4.4
🎉
EPS
+78
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
13 |
Strong Buy |
5 |
Hold |
19 |
Sell |
0 |
Strong Sell |
0 |
GILD Price Forecast Target
78.7 👉 104.3 +33%
GILD EPS Forecast
4.4 👉 6.5 +47%
Financials
Profit Margin
20 %
Revenue Growth
5.4 %
Dividend
$ 3.0
Held Percent
0.1% - Insiders
86.8% - Institutions
13.1% - Public
Major Fund Holders
-
💰 Blackrock Inc. $10.0B
-
💰 Vanguard Group Inc $8.9B
-
💰 Capital World Investors $6.0B
-
💰 Capital Research Global Investors $4.6B
-
💰 State Street Corporation $4.5B
Stock Ideas
Ron Baron Portfolio
Ron Baron is an American billionaire investor, entrepreneur, and the founder of Baron Capital Group, a well-known investment management firm. He is recognized for his long-term, growth-oriented investment approach and has built a successful track re…
Bill Gates Portfolio
With a portfolio valued at over $18 billion, the Bill & Melinda Gates Foundation Trust holds the endowment and funds the Bill & Melinda Gates Foundation. Bill and Melinda are the trustees for the Foundation Trust, and the endowment is managed by a t…
Howard Marks Portfolio
Meet Howard Marks, the co-founder and lead of Oaktree Capital Management, a Los Angeles-based investment firm that manages roughly $78 billion in investment capital. Marks has an impressive background in distressed debt, high yield bonds, and conver…
Jim Chanos Portfolio
Jim Chanos is a revered figure in the world of portfolio management, known for his expertise in short selling and his pivotal role in uncovering fraud at Enron and WorldCom. Hailing from Milwaukee and a graduate of Yale with an economics degree, Ch…📮FAQ
Some Frequently Asked Questions.
The Gilead Sciences, Inc. industry is Drug Manufacturers—General
The Gilead Sciences, Inc. sector is Healthcare
The Gilead Sciences, Inc. forecasted predicted Price to Earnings PE ratio is 12.1
The Gilead Sciences, Inc. Price to Earnings PE ratio is 17.8
The Market Capitalization of Gilead Sciences, Inc. is $98.14B
There are total of 1244668657 float shares with 86.8% held by Institutions and 0.1% held by insiders
The MGilead Sciences, Inc. forecasted Earnings per Share EPS is $6.5
The Gilead Sciences, Inc. Earnings per Share EPS is 4.4
The Gilead Sciences, Inc. company has $21624000000 gross profits with 20 profit margins
The Gilead Sciences, Inc. Earnings Growth is -0.088% with -0.087% quarterly earnings growth
The Gilead Sciences, Inc. Revenue is $27381999616 with 0.054 revenue growth
The price target for Gilead Sciences, Inc. stock is $104.3 for the high target and $69.8 for the low target
The consensus analyst recommendations for Gilead Sciences, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Gilead Sciences, Inc. is Buy, with the following breakdown:
- Buy: 13
- Strong Buy: 5
- Hold: 19
- Sell: 0
- Strong Sell: 0
The Beta of Gilead Sciences, Inc. is 0.4
The dividend of Gilead Sciences, Inc. is $3.0
The dividend yield of Gilead Sciences, Inc. is 0.0381%
The biggest institutional and mutual fund holders of Gilead Sciences, Inc. stock are
- Blackrock Inc.
- Vanguard Group Inc
- Capital World Investors
- Capital Research Global Investors
The Gilead Sciences, Inc. ESG Score is 78, with the following breakdown:
- E: 0.03
- S: 14.04
- G: 8.01